Multiple lines of correlative evidence support a role for angel homolog 2 (ANGEL2), a novel cancer-relevant RNA-binding protein, in the modulation of chemoresistance and survival of patients with ...

Concurrent inactivating mutations in STK11 and KEAP1 drive primary resistance to therapies, lead to worse outcomes in KRAS-mutated lung adenocarcinoma (KRASmut-LUAD) and are associated with metabolic ...

AbstractPurpose:. AKT inhibitors, such as capivasertib, have shown activity in specific patients with metastatic castration-resistant prostate cancer when combined with docetaxel although none have ...

Abstract. Conducting phase I trials is particularly challenging when dealing with late-onset dose-limiting toxicity (DLT) or when patient accrual is rapid relative to the DLT assessment window. In ...

Summary. Antibody–drug conjugates are an emerging treatment of non–small cell lung cancer. Some do not require biomarkers, whereas others require mutations and/or protein expression. New diagnostic ...

Doxorubicin-naïve patients with metastatic soft-tissue sarcoma were enrolled in this phase Ib study. Every 21 days, subjects received ribociclib daily for 7 days followed by 3 days of no treatment ...

Many cancers are curable if treated in time. This is the keynote of the educational campaign for the control of cancer. To reduce the delay in treatment is the first step in lessening the mortality ...

2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025Online ISSN 2159-8290 Print ISSN 2159-8274 ...

Immunotherapies like immune checkpoint inhibitors (ICI) have changed the standard of care for patients with cancer, often leading to durable responses. However, many patients remain or become ...

We describe a paradigm wherein combined high TLS and low tissue-resident exhausted CD8 + T cells are required for optimal response to PD-1 blockade in RCC. This analysis identifies key determinants of ...

AbstractBackground:. The five-year survival rate for colorectal cancer (CRC) remains at 14% despite improvements in early detection and the development of novel treatments, underscoring the need for ...

The dynamic interplay between tumor cells and γδT cells within the tumor microenvironment significantly influences disease progression and immunotherapy outcome. In this study, we delved into the ...